Other News

MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi

SOUTH SAN FRANCISCO, Calif., July 18, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today announced updates related to its hypertrophic cardiomyopathy (HCM) treatment portfolio, including lead therapeutic candidate, mavacamten. Patient screening has closed for the Phase 3 EXPLORER-HCM registrational clinical study to assess the effect of mavacamten in treating […]

Olivier Chaudoir Joins BioSig as Director of Marketing

Westport, CT, July 18, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing technology platform designed to address an unmet need for the electrophysiology (EP) marketplace, today announced that Mr. Olivier Chaudoir joined the Company as Director of Marketing. Mr. Chaudoir brings to […]

New study finds both components of blood pressure predict heart attack, stroke risk

OAKLAND, Calif., July 17, 2019 /PRNewswire/ — Both numbers in a blood pressure reading — the “upper” systolic and the “lower” diastolic — independently predicted the risk of heart attack or stroke in a very large Kaiser Permanente study that included more than 36 million blood pressure readings from more than 1 […]

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency

VANCOUVER, July 17, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has received written notification (the “Nasdaq […]

Corindus Adds Two New CorPath GRX Installations to HCA Healthcare Facilities

WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has installed CorPath® GRX Systems in two new hospitals affiliated with one of the nation’s largest hospital networks, HCA Healthcare. The new systems are now installed in hospital locations […]

Corindus Announces Regulatory Approval of CorPath GRX for Neurovascular Intervention in Australia and New Zealand

Expanded indication provides access to robotic technology in vascular procedures from head to toe July 17, 2019 06:45 AM Eastern Daylight Time WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it received approval from the Australian Therapeutic Goods Administration […]

Q’Apel Medical Announces FDA Clearance for Walrus Balloon Guide Catheter

FREMONT, Calif., July 17, 2019 /PRNewswire/ — Q’Apel Medical announced today that it received U.S. Food and Drug Administration clearance for its novel walrus Balloon Guide Catheter (BGC). In the neurovascular space where speed, reliability and performance are so critical to patient outcomes, physicians and patients demand that innovative technologies are best-in-class. The walrus BGC, […]

Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative

SAN DIEGO, July 16, 2019 /PRNewswire/ — Ambrx Inc. today announced that Bristol-Myers Squibb Company (“BMS”) has initiated a phase I clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of long-acting Relaxin for the potential treatment of heart failure (“HF”). Long-acting Relaxin is an investigational biologic produced using Ambrx’ proprietary expanded genetic code […]

Digital therapeutics leader Biofourmis to take part in pioneering heart failure research with Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI)

BOSTON, July 16, 2019 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics, has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). Biofourmis’ mobile platform BiovitalsHFTM will be leveraged in a study of patients with heart failure to monitor functional capacity and quality of life […]